<DOC>
	<DOCNO>NCT02062905</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety OTX-DP sustain release drug ( dexamethasone ) depot place canaliculus eyelid treatment sign symptom chronic allergic conjunctivitis .</brief_summary>
	<brief_title>Phase 2/3 Study Evaluating Efficacy Safety OTX-DP Treatment Chronic Allergic Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>least 18 year age either sex race positive history ocular allergy positive skin test reaction perennial allergen calculate bestcorrected visual acuity 0.7 logMAR good eye measure use ETDRS chart know contraindication sensitivity use investigational product medication component ocular surgical intervention within three ( 3 ) month prior Visit 1 study and/or history refractive surgery within past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>